CELU
What one share of Celularity holds
Pharmaceutical Preparations
We are a cellular and regenerative medicine company focused on advancing health longevity and redefining the standard of care for age-related disease using novel therapies derived from the post-partum human placenta. The objective of extending health longevity is to meaningfully reduce the duration and severity in which an individual experiences aging-related degenerative diseases and disorders associated with increased mortality towards the end of life.
Celularity’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.66 |
|---|---|
| Profit | −$1.63 |
| Cash and investments | $0.02 |
| Debt | $1.15 |
| Book value | −$1.21 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | $7.75 | −$113.06 | $15.11 | −$49.42 | — | −$286.79 |
| 2021 | $3.18 | −$14.93 | $0.93 | −$17.34 | — | $8.00 |
| 2022 | $1.20 | $0.95 | $0.35 | −$9.55 | — | $13.36 |
| 2023 | $1.28 | −$11.02 | $0.06 | −$2.23 | — | $2.11 |
| 2024 | $2.48 | −$2.64 | $0.01 | −$0.30 | — | $0.39 |
| 2025 | $1.04 | −$3.59 | — | −$0.52 | — | −$1.32 |